This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Analysts Name Top Biotech Stocks for 2010: BioBuzz

"Balance sheet concerns persist with small-cap names although top picks Rigel (RIGL), Isis Pharmaceuticals (ISIS), Cardiome (CRME), Array Biopharma (ARRY) and Ariad Pharmaceuticals (ARIA) have benefited from, or should benefit from meaningful partnership funding and support. With M&A as a major theme we continue to advise focus on antibody products, key therapeutics areas like hepatitis C, orphan indications, and companies with shared economics with larger partners."

Biogen Future in Flux as CEO Exits

(At 5:30 AM EST)

Will Carl Icahn be invited to Biogen Idec (BIIB) CEO Jim Mullen's retirement party?

I'm going out on a limb to say probably not. But then this may be the only easily answered question related to Mullen's planned retirement in June and its impact on Biogen's future.

Mullen announced Monday afternoon that he is stepping away from the company, both as CEO and as a director. He gave no specific reason for his departure, although a company spokesman told Dow Jones that Mullen was under no pressure from the board or investors to leave the company.

"Investors" means Icahn, naturally, since the well-known activist hedge fund manager has long taken a keen interest in Biogen. He's also been sharply critical of Mullen's tenure as CEO. Last year, Icahn used his significant ownership stake in Biogen to nominate and seat two directors to Biogen's 11-member board. (Two other Icahn director nominees were not elected.) Prior to that, Icahn pressured Biogen's board to sell the company outright. When a sale didn't happen, he accused Mullen and his management team of sandbagging the process.

When Mullen retires in June, he will have 21 years at the company under his belt. He's been chief executive since 2000, which encompasses CEO stints both before and after the 2003 merger with Idec Pharmaceuticals. Maybe Mullen simply felt it was time to move on.

Or maybe he grew tired of battling with Icahn and was looking ahead with dread to the company's next annual meeting in June when Icahn could once again try to get more of his chosen directors nominated to the board. Interestingly enough, Mullen is up for re-election as a director in June -- a tempting target for Icahn, for sure.

4 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,065.68 -7.15 -0.34%
NASDAQ 4,790.4040 +3.0870 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs